rubitecan

rubitecan

Oncology A topoisomerase inhibitor in trials for treating ovarian, colorectal, gastric, liver, lung, breast, pancreas, prostate, cervical, head & neck CA, myelodysplastic syndrome, CML, melanoma, glioma, sarcoma
References in periodicals archive ?
(The first topoisomerase inhibitors are given by injection, but a new one -- Orathecin, formerly named Rubitecan -- now waiting for FDA approval for pancreatic cancer, is taken orally.